From: Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
Baseline | Typical | Atypical | p value |
---|---|---|---|
PAH therapy, 0–3 months | n = 86 | n = 45 | |
None | 10 (11.6%) | 4 (8.9%) | 0.212 |
Monotherapy | 49 (57.0%) | 34 (75.6%) | |
Dual therapy | 21 (24.4%) | 6 (13.3%) | |
Triple therapy | 6 (7.0%) | 1 (2.2%) | |
n = 76 | n = 41 | ||
Monotherapy | 49 (64.5%) | 34 (82.9%) | 0.036 |
Dual and triple therapy | 27 (35.5%) | 7 (17.1%) | |
PAH therapy, 4–8 months | n = 83 | n = 42 | |
Monotherapy | 43 (51.8%) | 29 (69.0%) | 0.119 |
Dual therapy | 33 (39.8%) | 9 (21.4%) | |
Triple therapy | 7 (8.4%) | 4 (9.5%) | |
n = 83 | n = 42 | ||
Monotherapy | 43 (51.8%) | 29 (69.0%) | 0.065 |
Dual and triple therapy | 40 (48.2%) | 13 (31.0%) | |
PAH therapy, 9–15 months | n = 72 | n = 39 | |
Monotherapy | 30 (41.7%) | 20 (51.3%) | 0.576 |
Dual therapy | 35 (48.6%) | 15 (38.5%) | |
Triple therapy | 7 (9.7%) | 4 (10.3%) | |
n = 72 | n = 39 | ||
Monotherapy | 30 (41.7%) | 20 (51.3%) | 0.331 |
Dual and triple therapy | 42 (58.3%) | 19 (48.7%) |